Glasgow University study sheds light on Alzheimer's risk
The research, led by the University of Glasgow, published in the journal npj Dementia, found that while better memory, reasoning, and reaction times were linked to a lower risk of Alzheimer's disease up to 15 years later, this protective effect was significantly reduced in people with a higher genetic risk.
Researchers focused on the APOE e4 genotype, which is present in roughly one in four people and is the strongest known genetic predictor of late-onset Alzheimer's.
Read more: Glasgow drugs trial to use genetics to 'personalise' treatments
A single copy of the APOE e4 gene increases Alzheimer's risk threefold, while two copies raise the risk by twelvefold.
Dr Donald Lyall, senior lecturer in population brain health at the University of Glasgow's School of Health and Wellbeing, said: "Our study adds to the knowledge gap that exists on the relationship between genetic factors, cognitive health generally, and subsequent risk of dementia in later life.
"Our findings suggest that genetics plays a more significant role than previously thought and may influence the risk or protection conferred by other factors like premorbid cognitive health."
In the study, people with above-average reasoning ability were found to have a 36% lower risk of developing Alzheimer's within 15 years.
However, for those who also carried the APOE e4 gene, the risk reduction dropped to just 21%.
More strikingly, individuals with high reasoning skills but who carried the APOE e4 genotype were more likely to develop Alzheimer's than those with below-average reasoning but no genetic risk factor.
The researchers analysed data from over 252,000 UK Biobank participants aged 55 and older, with the average age at the start of the study being just over 62.
To ensure long-term accuracy, individuals diagnosed with Alzheimer's within two years of testing were excluded.
Researchers excluded individuals diagnosed with Alzheimer's within two years of cognitive testing.
The study reinforces the challenges in identifying effective therapies for Alzheimer's, particularly given the influence of genetic factors.
Read more: Public urged to shape health board's anti-racism strategy - how you can help
Dr Lyall said: "Our study has important implications regarding dementia; namely that genetics clearly plays a significant role in influencing someone's overall risk of Alzheimer's disease as they age."
The findings underscore the complex interplay between cognitive health and genetics and the challenges in developing therapies that can effectively prevent or treat Alzheimer's.
While cognitive resilience still matters, the research highlights the urgent need to understand genetic risk factors in the fight against one of the world's most devastating neurodegenerative conditions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Glasgow Times
2 hours ago
- Glasgow Times
Strathclyde partnership launches shipping research centre
The Oldendorff Research Centre for Sustainable Shipping, based in Glasgow, is a partnership between the University of Strathclyde and international shipping company Oldendorff Carriers. Formally established during a signing ceremony at Strathclyde's city centre campus, the centre will focus on research and practical solutions to deliver actionable progress in maritime decarbonisation. Read more: Glasgow study reveals 'significant role' of genetics in Alzheimer's disease Professor Stephen McArthur, executive dean of engineering and associate principal at the University of Strathclyde, said: "We are pleased to be working in partnership with Oldendorff, uniting Strathclyde's internationally recognised research capabilities with Oldendorff's deep operational expertise and knowledge. "By combining our strengths, we are creating new opportunities to drive forward the decarbonisation of the global shipping industry – an urgent challenge that demands innovative, practical solutions. "We look forward to delivering impact together through research, technology development, and knowledge exchange." The centre aims to address key evidence gaps in the industry transition, focusing on technological, operational, and human factors. This includes the impact of decarbonisation measures on crew, next-generation energy-efficient vessel design, alternative fuel systems, and AI-driven decision-support tools. Through its research, the centre hopes to further the scientific evidence base that informs maritime policymaking. As part of the Centre's activities, a scientific research paper on 'Round-trip Efficiency of Various E-fuels' is being produced. Professor Stephen McArthur, Executive Dean of Engineering and Associate Principal at Strathclyde, with Dr Torsten Barenthin, Director Research & Development at Oldendorff (Image: Supplied) Read more: 'This can potentially save lives': New device fitted on Glasgow mobile mast Dr Torsten Barenthin, director of research and development at Oldendorff, said: "Decarbonising the maritime sector is the greatest operational challenge the industry faces and will continue to face in the years ahead. "Addressing it requires not only collaboration, but also a willingness to engage with the difficult issues that remain unexamined in much of the current discourse. "The centre is designed to generate insights that extend beyond Oldendorff and deliver measurable impact across the global fleet."
The Independent
4 hours ago
- The Independent
Why two Alzheimer's drugs were rejected for use on the NHS
The National Institute for Health and Care Excellence (Nice) has rejected two Alzheimer's drugs, Donanemab and Lecanemab, for use on the NHS. Nice determined that the drugs offer only 'modest benefits at best,' delaying disease progression by four to six months in early stages. The decision was based on the drugs' limited benefits not justifying their high cost, estimated to be between £500 million and £1 billion annually for the NHS. Donanemab and Lecanemab are targeted antibody drugs that work by clearing amyloid protein buildup in the brain to slow cognitive decline. Scientists and doctors remain divided on the drugs' clinical significance, with some highlighting their potential while others raise concerns about the small benefits and serious side effects observed in trials.
Telegraph
7 hours ago
- Telegraph
Battle begins to get blocked Alzheimer's ‘wonder' drugs on NHS
The decision to block Alzheimer's 'wonder' drugs for use by NHS patients will be appealed against. The two breakthrough drugs, proven to slow the onset of Alzheimer's disease, have been rejected for use on the NHS by the National Institute for Health and Care Excellence (Nice). The watchdog chose to stand by its initial decision in final guidance published on Thursday, despite the drugs being approved by the medicines regulator. It means they will only be available privately in the UK. Nice insisted that the benefits were too small to justify the costs involved. Manufacturers of both drugs have confirmed they will now appeal. Bosses behind one of the drugs, donanemab, made by the pharmaceutical firm Lilly, said the system was 'broken' if it 'can't deliver scientific firsts to NHS patients'. Another said the decision 'protects a health service that is not yet ready to identify and manage' Alzheimer's patients. The outcome of the appeal could take up to four months to be reached. Charities described the decision as a 'painful setback' for patients and warned that the 'science was flying by while the system is failing'. Donanemab and lecanemab, the latter manufactured by Eisai, are targeted antibody drugs that slow down the early stages of Alzheimer's. They have been hailed as breakthrough drugs because they target a known cause of the disease – the build-up of a protein in the brain called amyloid – rather than just treating symptoms. Both drugs, delivered via an IV drip, bind to amyloid in the brain and help to clear the buildup and slow down cognitive decline. In clinical trials, donanemab slowed the rate at which memory and thinking get worse by more than 35 per cent, while for lecanemab it was 27 per cent. Results also suggest the drug leads to a slowing in the decline of everyday activities such as driving, enjoying hobbies and managing money. However, side effects of the drugs can be serious, including brain bleeds and the risk of death. In its final guidance, Nice recognised that the treatments delay progression of mild to moderate Alzheimer's by four to six months. But it said the medicines cannot be provided on the NHS because they are not good value for money and 'only provide modest benefits at best'. Lilly said it would appeal on the grounds that the decision was 'unreasonable' based on the evidence it had submitted. An appeal panel will hear the evidence the company presents, which will include charity and patient testimony, and decide whether to overturn the decision, with a result expected this autumn. Chris Stokes, the president and general manager of UK and northern Europe at Lilly, said: 'If the system can't deliver scientific firsts to NHS patients, it is broken. 'If the Government is to deliver on its goals to reduce lives lost to the biggest killers and put Britain at the forefront of transforming treatment for dementia, it must keep pace with licensed medical breakthroughs.' Gary Hendler, the regional chairman and chief executive of Eisai's European hub, said the company was 'dismayed' and 'very upset about what it means for people with Alzheimer's disease and their families'. 'This decision protects a health service that is not yet ready to identify and manage patients in the early stages of their illness,' he said. 'On top of this, this outcome demonstrates that Nice's appraisal process is simply not fit to evaluate medicines for early Alzheimer's disease. There are currently over 130 new drugs in development for Alzheimer's around the world.' Last year, NHS England published a briefing paper suggesting the cost of bringing the drugs to the health service could be £500 million to £1 billion per year. The drugs themselves cost around £20,000 to £25,000 per year, but with the need for regular brain scans and check-ups, the cost to the NHS would likely be between £50,000 and £100,000 per patient, it is understood. 'The science is flying, but the system is failing' Prof Fiona Carragher, the Alzheimer's Society's chief policy and research officer, said the decision was 'highly disappointing'. 'The reality we're faced with is that these treatments remain out of reach of both the NHS and most eligible people with Alzheimer's disease,' she said. 'In other diseases like cancer, treatments have become more effective, safer and cheaper over time. It's essential we see similar progress in dementia.' But she said that even if the drugs were approved, 'many patients wouldn't be able to access them because the health system isn't ready to deliver them'. 'The science is flying but the system is failing,' she added, calling on the Government to commit long-term investment to improve early diagnosis rates. Hilary Evans-Newton, the chief executive of Alzheimer's Research UK, said it was 'a painful setback for people affected by Alzheimer's, but sadly not a surprising one'. She added: 'The drugs' modest benefits, combined with the significant costs of delivering them in the NHS, meant they faced insurmountable challenges.' She said it sent a 'troubling signal' to the life science industry and was 'undermining confidence in the UK as a home for research, innovation and clinical trials'. 'Nice's decision should ring alarm bells for a Government that, only a year ago, pledged to make the UK a global leader in dementia treatments,' she added. 'Lack of long-term evidence' Helen Knight, the director of medicines evaluation at Nice, said: 'While we recognise the hope these treatments offer, the evidence shows they only provide modest benefits at best and substantial resources would be needed to provide them.' She said, while the committee accepted any benefits granting 'more time socialising, driving and being independent' would be meaningful, the lack of long-term evidence, 'substantial resources the NHS would need to commit' and risk of displacing other vital services meant it could not be approved. 'We realise today's news will be disappointing for many, but we now need to focus on the encouraging pipeline of new Alzheimer's drugs in development, a number of which are already earmarked for Nice evaluation,' she added. Drug firms and registered patient groups have until July 8 to appeal against the decision. A reformulation of lecanemab is being developed so it can be administered via an injection under the skin. Nice could then review the drug in this form. Almost one million people in the UK are living with dementia, including one in six over the age of 80. The figure is expected to reach 1.4 million by 2040 as Britain's population ages. Dr Jeremy Isaacs, national clinical director for dementia at NHS England, said: 'NHS England has a dedicated team preparing for the rollout of new Alzheimer's treatments. 'There are several other Alzheimer's treatments in development, and the NHS stands ready to offer patients access to new treatments as soon as they are deemed by regulators to be clinically and cost-effective.'
